<DOC>
	<DOCNO>NCT02658357</DOCNO>
	<brief_summary>The study 6-month , open-label , multiple center study approximately 50 stable subject diagnose schizophrenia schizoaffective disorder evaluate safety , tolerability , pharmacokinetics Risperidone 9-OH-Risperidone follow implantation two three , 300 mg Risperidone Implants .</brief_summary>
	<brief_title>Study Stabilized Schizophrenic Patients Evaluate Pharmacokinetics Risperidone 9-Hydroxy ( OH ) -Risperidone When Risperidone Administered From Polyurethane Implant</brief_title>
	<detailed_description>The study 6-month , open-label , study approximately 50 stable subject diagnose schizophrenia schizoaffective disorder evaluate safety , tolerability , pharmacokinetics Risperidone 9-OH-Risperidone follow implantation two three , 300 mg Risperidone Implants . Subjects diagnose schizophrenia schizoaffective disorder accord DSM-V stable daily 4 mg oral dose Risperidone least 8 week recruit study . Subjects stable 4 mg oral dose Risperidone implant two three , 300 mg , Risperidone Implants . All implant place inner aspect upper arm . Plasma concentration Risperidone active moiety measure prior placement Risperidone Implants , throughout implantation period , re-converting oral Risperidone follow removal Risperidone Implants .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>1 . Subject ( and/or subject 's authorized legal representative ) provide write informed consent 2 . Patient meet follow criterion : Outpatient status PANSS Total Score ≤ 80 screen PANSS score baseline ≥ 20 % change screening , patient participate study . A score ≤ 3 follow PANSS item : Conceptual disorganization Suspiciousness Hallucinatory behavior Unusual think content 3 . Subject male female 18 60 year age 4 . Subject diagnosis schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , 5th edition ( DSMV ) criteria 1 . Hospitalized required acute crisis intervention symptom exacerbation 60 day prior admission determine Investigator 2 . Subject history suicide attempt last year , opinion investigator currently imminent risk suicide 3 . Has current recent ( within 12 month ) DSMV diagnosis moderate severe substance use disorder ( except tobacco use disorder ) positive urine drug screen prohibit substance screen . 4 . Have impair hepatic ( ALT/AST &gt; 1.5 time high upper limit normal ) renal function ( eGFR &lt; 50 mL/min ) 5 . Previously define hypersensitivity Risperidone 6 . History neuromalignant syndrome ( NMS ) 7 . Electroconvulsive therapy within 6 month admission 8 . Requires current use agent strong inhibitor inducer cytochrome P450 2D6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>